

## **NOTIFICATION TO STOCK EXCHANGE**

### **COMPANY STATEMENT**

#### **Biocon Pharma Limited's facility at Bengaluru Concludes USFDA Surveillance and Inspection, With Zero Observations**

***Karnataka, Bengaluru, India, June 03, 2023***

This is to inform you that the USFDA concluded a surveillance and pre-approval inspection of Biocon Pharma Limited Oral Solid Dosage formulations manufacturing facility at Bengaluru on 2nd June 2023, with no observations.